Literature DB >> 29688904

Chronic total occlusion intervention of the non-infarct-related artery in acute myocardial infarction patients: the Korean multicenter chronic total occlusion registry.

Ji Young Park1, Byoung Geol Choi2, Seung-Woon Rha3, Tae Soo Kang4, Cheol Ung Choi3, Cheol Woong Yu5, Hyeon-Cheol Gwon6, In-Ho Chae7, Hyo-Soo Kim8, Hun Sik Park9, Seung-Hwan Lee10, Moo-Hyun Kim11, Seung-Ho Hur12, Yangsoo Jang13.   

Abstract

BACKGROUND: The Korean chronic total occlusion (CTO) registry was collected prospectively from 26 cardiovascular centers since May 2007. The aim of this study is to investigate the impact of a successful staged percutaneous coronary intervention (PCI) of CTO lesions in acute myocardial infarction (AMI) patients on clinical outcomes. PATIENTS AND METHODS: Among 2813 patients who underwent a staged PCI because of CTO lesions, 422 (15%) patients underwent primary PCI because of AMI. Among 422 patients, successful staged CTO-PCI was performed in 76%. The clinical outcomes were compared between the successful CTO-PCI group (n=321) and the failed CTO-PCI group (n=101). To adjust for potential confounders, a propensity score matching (PSM) analysis was carried out using the logistic regression model.
RESULTS: After the PSM analysis, two propensity-matched groups (85 pairs, n=170) were generated and the baseline characteristics were balanced. The incidence of total death (P=0.029) and non-ST-segment elevation myocardial infarction (NSTEMI, P=0.043) at 1 year was higher in the failed CTO-PCI group. Multivariate regression showed that successful CTO-PCI was an independent predictor of preventing mortality (hazard ratio, 0.21, P=0.048). In the subgroup analysis, the Kaplan-Meier curve showed that successful CTO-PCI had a lower incidence of total death (log-rank=0.004) and cardiac death (log-rank=0.005) up to 1 year in NSTEMI patients. Cox-proportional analysis showed that successful CTO-PCI was beneficial in patients with NSTEMI, hypertension, and non-left-anterior descending artery lesion for preventing mortality.
CONCLUSION: In this study, a staged successful CTO-PCI in AMI patients was associated with improved 1-year survival in the Korean population.

Entities:  

Mesh:

Year:  2018        PMID: 29688904     DOI: 10.1097/MCA.0000000000000630

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  5 in total

Review 1.  The Role of Multimodality Imaging for Percutaneous Coronary Intervention in Patients With Chronic Total Occlusions.

Authors:  Eleonora Melotti; Marta Belmonte; Carlo Gigante; Vincenzo Mallia; Saima Mushtaq; Edoardo Conte; Danilo Neglia; Gianluca Pontone; Carlos Collet; Jeroen Sonck; Luca Grancini; Antonio L Bartorelli; Daniele Andreini
Journal:  Front Cardiovasc Med       Date:  2022-05-02

2.  Outcomes after percutaneous coronary intervention and comparison among scoring systems in predicting procedural success in elderly patients (≥ 75 years) with chronic total occlusion.

Authors:  Ya-Min Su; Min Pan; Hai-Hua Geng; Rui Zhang; Yang-Yang Qu; Gen-Shan Ma
Journal:  Coron Artery Dis       Date:  2019-11       Impact factor: 1.439

3.  The 11-Year Prognostic Impact of Chronic Total Occlusion in the Noninfarct-Related Coronary Artery on Patients with Acute Myocardial Infarction.

Authors:  Xuanqi An; Jingang Yang; Kefei Dou; Yuejin Yang
Journal:  J Interv Cardiol       Date:  2021-03-17       Impact factor: 2.279

4.  A comparison of long-term clinical outcomes between percutaneous coronary intervention (PCI) and medical therapy in patients with chronic total occlusion in noninfarct-related artery after PCI of acute myocardial infarction.

Authors:  Qing Qin; Lu Chen; Lei Ge; Juying Qian; Jianying Ma; Junbo Ge
Journal:  Clin Cardiol       Date:  2022-01-06       Impact factor: 2.882

Review 5.  Does multivessel revascularization fit all patients with STEMI and multivessel coronary artery disease? A systematic review and meta-analysis.

Authors:  Meng-Jin Hu; Xiao-Song Li; Chen Jin; Yue-Jin Yang
Journal:  Int J Cardiol Heart Vasc       Date:  2021-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.